Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0009-8981(78)90490-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spectrum and Prevalence of Rare Variants and Their Association with Familial Dysbetalipoproteinemia.
Int J Mol Sci
November 2024
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Petroverigsky per. 10, Bld. 3, 101000 Moscow, Russia.
Familial dysbetalipoproteinemia (FD) is a highly atherogenic, prevalent genetically based lipid disorder. About 10% of FD patients have rare variants associated with autosomal dominant FD. However, there are insufficient data on the relationship between rare variants and FD.
View Article and Find Full Text PDFDoes Adopting Western Low-density Lipoprotein Cholesterol Targets Expose Indians to a Higher Risk of Cardiovascular Events? Expert Opinion From the Lipid Association of India.
J Assoc Physicians India
October 2024
Professor and Director, University of California, Irvine School of Medicine, Irvine, California, United States.
Adverse cardiovascular (CV) events have declined in Western countries due at least in part to aggressive risk factor control, including dyslipidemia management. The American and European (Western) dyslipidemia treatment guidelines have contributed significantly to the reduction in atherosclerotic cardiovascular disease (ASCVD) incidence in the respective populations. However, their direct extrapolation to Indian patients does not seem appropriate for the reasons described below.
View Article and Find Full Text PDFBeyond the Guidelines: Perspectives on Management of Pediatric Patients with Hypertriglyceridemia.
Curr Atheroscler Rep
November 2024
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Purpose Of Review: To provide a comprehensive overview of hypertriglyceridemia (HTG) in youth, identifying gaps in categorizing triglyceride (TG) levels and management strategies, and exploring new therapies for TG reduction.
Recent Findings: Non-fasting TG levels as important cardiovascular (CV) risk indicators, with HTG's pathophysiology involving genetic and secondary factors affecting TG metabolism. Emerging treatments, including those affecting the lipoprotein lipase complex and inhibiting proteins like apoC3 and ANGPTL3, show promise.
Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis.
Endocr Pract
November 2024
Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
Background: No meta-analysis has holistically analyzed and summarized the safety and therapeutic efficacy of the newer RNA interference (RNAi) therapies, olezarsen, plozasiran, and zodasiran, in managing conditions associated with hypertriglyceridemia (HTG).
Methods: Randomized controlled trials (RCTs) involving patients with HTG or mixed hyperlipidemia (MHL) receiving either olezarsen, plozasiran, or zodasiran in the intervention arm and a placebo in the control arm were searched through electronic databases. The primary outcome was the safety profile of the drugs studied; secondary outcomes included the percent change from baseline (CFB) in the lipid levels, including triglyceride (TG).
Article Synopsis
- The FinnDiane Study has been researching diabetic kidney disease for over 25 years to understand how it happens, especially looking at things like blood sugar levels and fat in the body.
- They found that problems like high blood sugar, extra fat, and high cholesterol can make kidney disease worse, and some people can even get better after starting treatment.
- There is still a big problem with kidney disease for people with type 1 diabetes, so new treatments are really needed, and it's important to manage things like weight and blood sugar levels to help protect the kidneys.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!